Boston Scientific agrees to buy VC-backed Augmenix for up to $600 mln
Boston Scientific has agreed to acquire Waltham, Massachusetts-based Augmenix, which develops radiation oncology products to treat prostate cancer. The deal includes $500 million in cash, and up to $100 million based on milestones. Augmenix, previously known as SpaceOAR and founded in 2008, had raised funding from Excelestar Ventures, Ascension Health Ventures, Catalyst Health Ventures, Pinnacle Ventures and the Sparta Group.
7 September 2018•1 min read
